Table 6.

Clinical features of patients with SCN1A variants

Patient	Sex	Age of onset	Clinical onset	All types of seizures	EEG features	Fever sensitivity	Vaccine-associated	Developmental delay	Other symptoms	Follow-up period	All types of ASMs used	Diagnosis
1	M	9 months	FS	FS+ SGS	N	+	−	−	Language delay	18 months	VPA	GEFS+
2	F	4 months	FMS	FMS MS	N	+	−	+	Language delay	24 months	LEV, PB	DS
3	F	5 months	FS	FS MS	N	+	+	−	Language delay	5 years	LEV, PB	DS
4	F	4.5 months	FS	FS MS	N	+	+	−	Language delay	6 years	LEV, PB	DS
5	F	9 days	FMS	FS FIAS	Right centrotemporal	+	−	−	−	4 years	VPA	GEFS+
6	M	3 months	FS	Febrile SE SGS MS	Slow background multifocal	+	+	+	Ataxia	5 years	VPA, CLB STP	DS
7	F	3 months	FS	Febrile SE SGS MS	Slow background multifocal	+	−	+	Ataxia	3 years	VPA, CLB	DS
8	F	6 months	FMS	Febrile SE SGS MS	N	+	+	+	Ataxia	3 years	VPA, CLB	DS
9	F	12 months	FS	Febrile SE SGS	Bilateral centrotemporal	+	−	−	Language delay	12 months	VPA	GEFS+
10	F	5 months	FS	FS SGS	N	+	−	+	Ataxia	3 years	VPA, CLB	DS
11	F	3 months	FMS	FS SGS FMS	Slow background multifocal	+	−	+	Ataxia	3 years	VPA, CLB	DS
12	M	9 months	FS	FS MS	N	+	−	+	Ataxia	4 years	VPA	DS
13	F	2.5 years	FS	FS SGS	Bifrontal generalized	−	−	−	−	1.5 years	VPA	GEFS+
14	M	5 months	FS	FS SGS	Right centrotemporal	+	−	+	Ataxia	4 years	VPA, LEV, STP, CLB	DS
15	M	2.5 years	FS	FS+ MS	N	+	−	−	−	5 years	PB	GEFS+
16	M	3 months	FS	FS SGS	Right centroparietal	+	−	+	Language delay, ataxia	6 years	PB	DS
17	M	6 months	FS	Febrile SE SGS MS	Left centro-parietal occipital	+	−	+	Ataxia	9 years	VPA, CLB	DS
18	F	1.5 years	FS	FS+ SGS	N	+	−	−	−	4 years	VPA	GEFS+

DS, Dravet syndrome; GEFS+, genetic epilepsy with febrile seizures plus; EEG, electroencephalogram; ASMs, antiseizure medications; M, male; F, female; N, normal; FS, febrile seizures; MS, myoclonic seizures; FMS, focal motor seizures; SE, status epilepticus; SGS, secondary generalized seizure; FIAS, focal impaired awareness seizures; LEV, levetiracetam; VPA, valproic acid; PB, phenobarbital; CLB, clobazam; STP, stiripentol.